Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Accuray Incorporated is a U.S.-based medical technology company specializing in the development, manufacture, and sale of advanced radiation therapy systems used for the treatment of cancer and certain neurological disorders. The company operates within the medical devices and radiation oncology industries, focusing on precision-based, image-guided radiotherapy solutions designed to improve clinical outcomes while minimizing damage to healthy tissue.
Accuray’s primary revenue drivers are its proprietary radiation therapy platforms, software, service contracts, and related upgrades. Its flagship systems include CyberKnife and Radixact, which are differentiated by real-time imaging, robotic delivery, and adaptive treatment capabilities. Founded in 1990, Accuray evolved from a research-driven startup into a publicly traded company following its initial public offering in 2007, expanding its portfolio and global footprint through continuous product development and international distribution.
Business Operations
Accuray generates revenue through the sale of capital equipment, recurring service and maintenance contracts, software licenses, and system upgrades. Its core operating segments are centered on CyberKnife Systems, which provide robotic radiosurgery for complex tumors, and Radixact Systems, which deliver helical tomotherapy for advanced intensity-modulated radiation therapy. Service revenue represents a significant and growing portion of total revenue, reflecting long-term customer relationships and installed base expansion.
The company operates domestically in the United States and internationally through direct sales teams and distributors across Europe, Asia-Pacific, and other global markets. Accuray controls proprietary treatment planning software, imaging technologies, and delivery platforms integral to its systems. Its operations include wholly owned subsidiaries that manage regional sales, service, and support, while manufacturing and system integration are primarily conducted in the United States.
Strategic Position & Investments
Accuray’s strategic direction emphasizes expanding its installed base, increasing recurring revenue through service contracts, and enhancing system capabilities through software-driven innovation. Growth initiatives focus on adaptive radiotherapy, workflow automation, and improved treatment accuracy, aligning with broader trends in personalized and value-based cancer care.
The company has historically pursued targeted acquisitions and internal investments to strengthen its technology stack, including enhancements to imaging, motion management, and treatment planning software. Accuray continues to invest in emerging applications of stereotactic radiosurgery and hypofractionated treatment regimens, positioning itself in clinically complex segments of the radiation oncology market where precision and differentiation are critical.
Geographic Footprint
Accuray is headquartered in Madison, Wisconsin, and maintains a global operational presence spanning North America, Europe, and Asia-Pacific. The company has established market positions in key countries such as the United States, Japan, China, and major European nations, supported by a combination of direct operations and third-party distributors.
International markets account for a substantial portion of system placements, reflecting the global demand for advanced radiation therapy technologies. Accuray’s international influence includes long-term service agreements, clinical partnerships, and regional subsidiaries that support localized regulatory, service, and commercial requirements.
Leadership & Governance
Accuray is led by an executive team with experience across medical technology, healthcare operations, and global commercialization. The company’s leadership emphasizes innovation, disciplined capital allocation, and expanding access to advanced cancer treatment technologies while maintaining regulatory and clinical rigor.
Key executives include:
- Suzanne D. Winter – President and Chief Executive Officer
- Thomas J. Price – Chief Financial Officer
- Joshua H. Levine – Chief Legal and Administrative Officer
- Chirag J. Patel – Chief Commercial Officer
- Jeffrey L. Beach – Chief Operations Officer
The company operates under a board-governed structure typical of publicly traded U.S. medical device firms, with oversight aligned to long-term shareholder value, regulatory compliance, and patient safety.